National Cancer Institute; Notice of Closed Meeting, 57917 [2024-15579]

Download as PDF Federal Register / Vol. 89, No. 136 / Tuesday, July 16, 2024 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Complementary & Integrative Health; Notice of Meeting khammond on DSKJM1Z7X2PROD with NOTICES Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council for Complementary and Integrative Health. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend in person and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session can also be accessed at the following NIH Videocast URL link https://videocast.nih.gov The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Council for Complementary and Integrative Health Date: September 13, 2024. Closed: 9:00 a.m. to 10:30 a.m. Agenda: To review and evaluate grant applications Place: National Institutes of Health, 31 Center Drive, Building 31C/6th Floor, Conference Room A&B, Bethesda, MD 20892, In Person. Open: 10:40 a.m. to 4:00 p.m. Agenda: Reports and Updates about Recent and Ongoing NCCIH Led or Involved Activities by NCCIH staff and its Director. Place: National Institutes of Health, 31 Center Drive, Building 31C 6th Floor, Conference Room A&B, Bethesda, MD 20892, In Person. Contact Person: Martina Schmidt, PHD, Director, Division of Extramural Activities, National Center for Complementary & Integrative Health, NIH, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892, (301) 594–3456, schmidma@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should be less than 700 words in length, and should include the name, email address, telephone number and VerDate Sep<11>2014 16:55 Jul 15, 2024 Jkt 262001 when applicable, the business or professional affiliation of the interested person. Any member of the public may submit written comments no later than August 30th, 2024 (14 days before the council meeting). In the interest of security, NIH has procedures at https://www.nih.gov/ about-nih/visitor-information/campusaccess-security for entrance into oncampus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: https:// www.nccih.nih.gov/news/events/ advisory-council-88th-meeting, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Alternative Medicine, National Institutes of Health, HHS) Dated: July 11, 2024. Victoria E. Townsend, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–15583 Filed 7–15–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 57917 discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; JUN2024 Cycle 47 NExT SEP Committee Meeting. Date: August 13, 2024. Time: 10:00 a.m. to 2:00 p.m. Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio. Place: National Institutes of Health, 9000 Rockville Pike, Building 31, Room 3A44, Bethesda, Maryland 20892 (Virtual Meeting). Contact Persons: Barbara Mroczkowski, Ph.D., Executive Secretary, Discovery Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, Maryland 20817, 301–496–4291, mroczkoskib@ mail.nih.gov. Toby Hecht, Ph.D., Executive Secretary, Development Experimental Therapeutics Program, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 3W110, Rockville, Maryland 20850, 240–276–5683, toby.hecht2@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: July 10, 2024. David W. Freeman, Supervisory Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–15579 Filed 7–15–24; 8:45 am] National Cancer Institute; Notice of Closed Meeting BILLING CODE 4140–01–P Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the DEPARTMENT OF HEALTH AND HUMAN SERVICES PO 00000 Frm 00075 Fmt 4703 Sfmt 4703 Substance Abuse and Mental Health Services Administration Meeting of the Substance Abuse and Mental Health Services Administration, Center for Mental Health Services National Advisory Council Substance Abuse and Mental Health Services Administration, HHS. ACTION: Notice. AGENCY: Notice is hereby given of the meeting on August 27, 2024, of the Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Mental Health Services National Advisory Council (CMHS NAC). The meeting is open to the public SUMMARY: E:\FR\FM\16JYN1.SGM 16JYN1

Agencies

[Federal Register Volume 89, Number 136 (Tuesday, July 16, 2024)]
[Notices]
[Page 57917]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-15579]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The purpose of this meeting is to evaluate requests 
for preclinical development resources for potential new therapeutics 
for the treatment of cancer. The outcome of the evaluation will provide 
information to internal NCI committees that will decide whether NCI 
should support requests and make available contract resources for 
development of the potential therapeutic to improve the treatment of 
various forms of cancer. The research proposals and the discussions 
could disclose confidential trade secrets or commercial property such 
as patentable material, and personal information concerning individuals 
associated with the proposed research projects, the disclosure of which 
would constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; JUN2024 Cycle 47 NExT SEP Committee Meeting.
    Date: August 13, 2024.
    Time: 10:00 a.m. to 2:00 p.m.
    Agenda: To evaluate the NCI Experimental Therapeutics Program 
Portfolio.
    Place: National Institutes of Health, 9000 Rockville Pike, 
Building 31, Room 3A44, Bethesda, Maryland 20892 (Virtual Meeting).
    Contact Persons: Barbara Mroczkowski, Ph.D., Executive 
Secretary, Discovery Experimental Therapeutics Program, National 
Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, 
Maryland 20817, 301-496-4291, [email protected].
    Toby Hecht, Ph.D., Executive Secretary, Development Experimental 
Therapeutics Program, National Cancer Institute, NIH, 9609 Medical 
Center Drive, Room 3W110, Rockville, Maryland 20850, 240-276-5683, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: July 10, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee 
Policy.
[FR Doc. 2024-15579 Filed 7-15-24; 8:45 am]
BILLING CODE 4140-01-P


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.